INTERVIEW: Philips' new commercial model for ultrasound eschews heavy capital investment
This article was originally published in Clinica
Executive Summary
Innovation is critical for medtech companies to stay ahead of the game and ensure continuous growth. But sometimes, this innovation does not necessarily have to come in the form of new technologies. Neil Mesher, managing director of Philips Healthcare UK & Ireland, tells Tina Tan how the company has developed a new ultrasound service – of which data analytics is a key enabler – that not only addresses fundamental challenges faced by mature healthcare systems but potentially reinvigorate revenue stream
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.